<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280302</url>
  </required_header>
  <id_info>
    <org_study_id>VESTHJXXIII</org_study_id>
    <nct_id>NCT04280302</nct_id>
  </id_info>
  <brief_title>Virtual Reality-based Rehabilitation</brief_title>
  <acronym>VRVEST</acronym>
  <official_title>Realitat Virtual Com a Tractament Coadjuvant en rehabilitació Vestibular</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitat Pompeu Fabra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitat Pompeu Fabra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vertigo / dizziness, imbalance and other symptoms related to vestibular pathology have a life
      prevalence of 7.4%. Peripheral and unilateral vestibulopathy are among the most common types,
      and in some patients the symptoms become chronic and disabling, which makes it difficult for
      them to lead a normal life and has a significant socio-economic impact. In recent years, the
      effect of vestibular rehabilitation with virtual reality has been studied and positive
      results have been obtained when compared with traditional rehabilitation, but despite
      rehabilitation there is patients who are still chronic, and the reasons for this prognostic
      variability are still unknown and require further treatment. Virtual reality-based
      stimulation can play a significant role as an adjunct to conventional vestibular
      rehabilitation, improving its effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change pre-post treatment in the Dizziness handicap inventory (DHI) (0-100)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in Posturography (Wii+software RombergLab)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in Test up and go (TUG)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in Berg Scale (0-56)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in Tinneti Test (1-28)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in Simulator Sickness Questionnaire (SSQ) (0-14)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in the Video-head impulse test (vHIT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in the Barthel Index (0-100)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change pre-post treatment in the SF 12 Test (0-100)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change within subjects from baseline to the end of week 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Patients With Unilateral Peripheral Vestibular Deficits</condition>
  <arm_group>
    <arm_group_label>Virtual reality based therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual Reality-based Rehabilitation</intervention_name>
    <description>VR-based eye stabilization exercises and balance exercises</description>
    <arm_group_label>Virtual reality based therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conventional Therapy</intervention_name>
    <description>Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises</description>
    <arm_group_label>Conventional Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral vestibular deficit

          -  Vestibular neuritis

          -  Sudden hearing loss with vestibular involvement

          -  Labyrinthitis

          -  Ménière's disease

          -  Vestibular Shwannoma

          -  Benign paroxysmal positional vertigo

          -  Vestibular symptoms (vertigo, dizziness, imbalance, gait instability, kinosis and / or
             oscillopsy) chronic (more than 6 weeks of evolution)

          -  Over 18 years old

        Exclusion Criteria:

          -  Failure to meet some of the inclusion criteria

          -  Neurological, traumatological, rheumatological, ophthalmological or systemic pathology
             that may interfere with the balance

          -  Inability to understand participation in the study

          -  Non-acceptance to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Sáez Felipe</last_name>
    <role>Principal Investigator</role>
    <affiliation>ssaezfelipe@gmail.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Sáez Felipe</last_name>
    <phone>+34977295800</phone>
    <email>ssaezfelipe@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosa M San Segundo</last_name>
    <phone>+34977295800</phone>
    <email>rosamaria.sansegundo@urv.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Maria San Segundo Mozo</last_name>
      <phone>+34977295800</phone>
      <email>rosamaria.sansegundo@urv.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitat Pompeu Fabra</investigator_affiliation>
    <investigator_full_name>Paul Verschure</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>vestibular</keyword>
  <keyword>unilateral vestibular</keyword>
  <keyword>virtual reality</keyword>
  <keyword>rehabilitation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

